Palonosetron Hydrochloride 135729-62-3 Antiemetic Chemical Powder High Purity in Stock Manufacturer Plant

• CAS No.: 135729-62-3
• Formula: C19h25cln2o
• EINECS: 680-630-6
• Type: Pharmaceutical Intermediates
• Appearance: Powder
• Quality: Refined
• Model NO.: chemical powder
• Colour: White
• Purity: 99.0%
• Impurity: 0.5%
• Assay: 99.0%
• Package: 1kg Per Bag
• Transport Package: 1kg
• Specification: 1kg
• Trademark: Hong Kongda
• Origin: Jinan
• HS Code: 2934999099
• Production Capacity: 5000kg Per Year

Product Description

Palonosetron Hydrochloride Chemical Properties

Melting point	>290°C
alpha	D25 -94.1° (c = 0.4 in water)
storage temp.	Inert atmosphere,Store in freezer, under -20°C
form	Solid
color	White to Off-White

The product is a drug to inhibit nausea and vomiting, which is a new type highly selective, high-affinity 5-HT3 receptor antagonist that can block the vomiting reflex center peripheral neurons presynaptic 5-HT. Receptor excitement directly affects the central nervous system in 5-HT. Impulse receptor excitement generated by the role of vagal afferent nerve after area, blocking the vagus nerve endings in the gut, preventing signals to 5-HT. Receptor trigger zone can reduce the incidence of nausea and vomiting. Central clinically for the treatment of acute severe emetogenic chemotherapy induced delayed nausea and vomiting. Because of its high curative effect, little side effect, long half-life (about 40 h), small dosage, and so on, it has attracted much attention.
With 1,2,3,4-tetrahydro-1-naphthoic acid as the starting material, the split, amination, reduction, cyclization, salt of palonosetron hydrochloride granisetron.
Clinical studies showed that palonosetron can be used safely with corticosteroids, analgesics, antiemetics, antispasmodics and anticholinergic drugsas the starting material, the split, amination, reduction, cyclization, salt of palonosetron hydrochloride granisetron.
Murine tumor model studies indicate that palonosetron does not inhibit the five kinds of chemotherapy drugs studied (cisplatin, cyclophosphamide, cytarabine, doxorubicin and mitomycin C) anti-cancer activity.